4527 — Rohto Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Rohto Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	181,287	199,646	238,664	270,840	308,625
Cost of Revenue
Gross Profit	106,961	116,170	137,421	157,286	174,939
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	161,937	171,583	205,999	231,708	271,756
Operating Profit	19,350	28,063	32,665	39,132	36,869
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,006	27,874	34,290	41,518	42,331
Provision for Income Taxes
Net Income After Taxes	16,770	21,188	26,430	31,395	30,952
Minority Interest
Net Income Before Extraordinary Items
Net Income	16,743	21,128	26,378	30,938	31,006
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	16,743	21,127	26,377	30,936	31,003
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	77.8	97.5	121	140	149
Dividends per Share